Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting.
Purple Squirrel Economics, New York, NY, USA. firstname.lastname@example.org.
Current strategies for risk stratification of patients with acute myeloid leukemia assign approximately 40% of patients to the intermediate-risk group, where uncertainty about optimal therapy still persists.
Appl Health Econ Health Policy 2019;17(6):827-839.
Pubmed ID: 31392669